$IBRX ImmunityBio receives FDA approval for expanded ANKTIVA use.

By Nexqual Desk ·

Tickers: $IBRX

$IBRX ImmunityBio receives FDA approval for expanded ANKTIVA use.

• The FDA expanded the use of ANKTIVA to include patients with papillary-only tumors.

• This covers the 85% of the NMIBC patient population previously excluded from the label.

Source: SEC 8-K, Oct 14, 2026.

0 likes

Posted on Nexqual Sonar — the social network for the stock market. Not financial advice.

Data source: Nexqual. Last updated: October 16, 2026 at 04:21 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt